<DOC>
	<DOCNO>NCT01896479</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety oral cabozantinib 60 mg dose compare 140 mg dose subject progressive , metastatic MTC . It test low dose result similar progression free survival ( PFS ) overall response rate ( ORR ) few adverse event compare PFS , ORR adverse event find previous clinical trial 140 mg .</brief_summary>
	<brief_title>A Study Two Different Doses Cabozantinib ( XL184 ) Progressive , Metastatic Medullary Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>1 . The subject histologically confirm diagnosis MTC . 2 . All subject need test RET mutational status . If subject documentation confirm RET mutation , sample tumor ( take either screening procedure within 6 month prior randomization ) need test . 3 . The subject measurable disease per RECIST 1.1 metastatic determine investigator base upon computerized tomography ( CT ) , magnetic resonance imaging ( MRI ) , PET scan , bone scan , Xray take within 28 day randomization . 4 . The subject document worsen disease ( progressive disease ) screening compare previous CT , PETor MRI scan , bone scan , Xray determine investigator per RECIST 1.1 qualify screening image take within 28 day prior randomization compare previous image take within 14 month qualify screening image . 5 . The subject recover baseline CTCAE v4.0 ( Common Terminology Criteria Adverse Events , version 4.0 ) ≤ Grade 1 toxicity relate prior treatment , unless AE ( ) clinically nonsignificant and/or stable supportive therapy . 6 . The subject Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 screening . 7 . The subject adequate organ marrow function 8 . The subject capable understanding comply protocol requirement sign informed consent document . 9 . Sexually active fertile subject partner must agree use medically accept method contraception ( eg , barrier method , include male condom , female condom , diaphragm spermicidal gel ) course study 4 month last dose study treatment . 1 . The subject previously receive cabozantinib . 2 . Receipt type small molecule kinase inhibitor hormonal therapy within 28 day 5 halflives compound active metabolite , whichever short , randomization . 3 . Receipt systemic antitumor therapy within 28 day randomization ( 42 day nitrosoureas or/ mitomycin C ) . 4 . Receipt type investigational agent within 28 day randomization . 5 . Receipt radiation therapy within 28 day ( 14 day radiation bone metastasis ) randomization radionuclide treatment within 42 day randomization . Subject ineligible clinically relevant ongoing complication prior radiation therapy . 6 . The subject untreated and/or active ( progress require anticonvulsant corticosteroid symptomatic control ) central nervous system ( CNS ) metastasis . Must complete radiation therapy ≥ 28 day prior randomization stable without corticosteroid anticonvulsant treatment ≥ 10 day . 7 . Treatment therapeutic dos oral anticoagulant platelet inhibitor ( example warfarin clopidogrel ) . 8 . The subject uncontrolled , significant intercurrent illness include , limited , cardiovascular disorder , gastrointestinal disorder , active infection , nonhealing wound , recent surgery . 9 . Corrected QT interval calculate Fridericia formula ( QTcF ) &gt; 500 m within 28 day randomization . 10 . The subject unable swallow multiple tablet capsule . 11 . The subject previously identify allergy hypersensitivity component study treatment formulation . 12 . The subject pregnant breastfeeding . 13 . The subject diagnosis another malignancy within 2 year randomization , except superficial skin cancer , localize , lowgrade tumor deem cured treated systemic therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>thyroid cancer</keyword>
	<keyword>medullary thyroid cancer</keyword>
</DOC>